Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Raymond James 

Karo Pharma AB diskutieren

Karo Pharma AB

WKN: A14YW4 / Symbol: KARO / Name: Karo Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

5,44 €
-0,18 %

Einschätzung Buy
Rendite (%) -
Kursziel 26,95
Veränderung
Endet am 21.07.24

Karooooo Ltd. (NASDAQ: KARO) had its price target raised by analysts at Raymond James from $27.00 to $30.00. They now have an "outperform" rating on the stock.
Ratings data for KARO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 30,66
Veränderung
Endet am 24.07.24

Karooooo Ltd. (NASDAQ: KARO) had its price target lowered by analysts at Morgan Stanley from $37.00 to $34.00. They now have an "overweight" rating on the stock.
Ratings data for KARO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 30,83
Veränderung
Endet am 31.07.24

Karooooo Ltd. (NASDAQ: KARO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.
Ratings data for KARO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 24,67
Veränderung
Endet am 13.10.24

Karooooo Ltd. (NASDAQ: KARO) had its price target lowered by analysts at Raymond James from $30.00 to $26.00. They now have an "outperform" rating on the stock.
Ratings data for KARO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 26,54
Veränderung
Endet am 24.01.25

Karooooo Ltd. (NASDAQ: KARO) had its price target raised by analysts at Raymond James from $26.00 to $29.00. They now have an "outperform" rating on the stock.
Ratings data for KARO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 28,46
Veränderung
Endet am 24.01.25

Karooooo Ltd. (NASDAQ: KARO) had its price target lowered by analysts at Morgan Stanley from $34.00 to $31.00. They now have an "overweight" rating on the stock.
Ratings data for KARO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 29,08
Veränderung
Endet am 22.04.25

Karooooo Ltd. (NASDAQ: KARO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
Ratings data for KARO provided by MarketBeat